Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds

Microbiology and Immunology

Volumn 52, Issue 8, 2008, Pages 383-391

  Maki, Katsuyuki ^a   Matsumoto, Satoru ^a   Watabe, Etsuko ^a   Iguchi, Yumi ^a   Tomishima, Masaki ^a   Ohki, Hidenori ^a   Yamada, Akira ^a   Ikeda, Fumiaki ^a   Tawara, Shuichi ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Candida albicans; Echinocandin; Pharmacodynamics; Serum MIC

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; ANTIFUNGAL AGENT; LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASSAY; CANDIDA ALBICANS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INVASIVE CANDIDIASIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PREDICTION; SERUM; ANIMAL; CANDIDIASIS; DRUG EFFECT; EVALUATION; FUNGUS HYPHAE; GROWTH, DEVELOPMENT AND AGING; INSTITUTE FOR CANCER RESEARCH MOUSE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MORTALITY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ANIMALIA; CANDIDA ALBICANS;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; ECHINOCANDINS; HYPHAE; LIPOPROTEINS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; SERUM; TREATMENT OUTCOME;

EID: 54749150650     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00053.x     Document Type: Article

References (34)

1. Cappelletty D., Eiselstein-McKitrick K. (2007) The echinocandins. Pharmacotherapy 27: 369-88. Review.
2. Denning D.W. (2003) Echinocandin antifungal drugs. Lancet 362: 1142-51. Review.
3. Douglas C.M., D'Ippolito J.A., Shei G.J., Meinz M., Onishi J., Marrinan J.A. et al. (1997) Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 41: 2471-9.
4. Wagner C., Graninger W., Presterl E., Joukhadar C. (2006) The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78: 161-77.
5. Wang W., Li Q., Hasvold L., Steiner B., Dickman D.A., Ding H. et al. (2003) Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I). Bioorg Med Chem Lett 13: 489-93.
6. Ikeda F.,Wakai Y., Matsumoto S., Maki K.,Watabe E., Tawara S. et al. (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44: 614-18.
7. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N. et al. (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44: 57-62.
8. Fujie A., Iwamoto T., Sato B., Muramatsu H., Kasahara C., Furuta T. et al. (2001) FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties. Bioorg Med Chem Lett 11: 399-402.
9. Barrett D., Tanaka A., Harada K.,Watabe E., Maki K., Ikeda F. (2001) Synthesis and biological activity of novel macrocyclic antifungals: modification of the tyrosine moiety of the lipopeptidolactone FR901469. Bioorg Med Chem Lett 11: 1843-9.
10. Klein L.L., Li L., Chen H.-J., Curty C.B., DeGoey D.A., Grampovnik D.J. et al. (2000) Total synthesis and antifungal evaluation of cyclic aminohexapeptides. Bioorg Med Chem 8: 1677-96.
11. Lebouvier N., Pagniez F., DuflosM., Le Pape P., Na Y.M., Le Baut G. et al. (2007) Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorg Med Chem Lett 17: 3686-9.
12. Salama S.M., Atwal H., Gandhi A., Simon J., Poglod M., Montaseri H. et al. (2001) In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents. Antimicrob Agents Chemother 45: 2420-6.
13. Takrouri K., Oren G., Polacheck I., Sionov E., Shalom E., Katzhendler J. et al. (2006) Synthesis and antifungal activity of a novel series of alkyldimethylamine cyanoboranes and their derivatives. J Med Chem49: 4879-85.
14. Yamazaki K., Kaneko Y., Suwa K., Ebara S., Nakazawa K., Yasuno K. (2005) Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure. Bioorg Med Chem 13: 2509-22.
15. Rex J.H., Pfaller M.A.,Walsh T.J., Chaturvedi V., Espinel-Ingroff A., Ghannoum M.A. et al. (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14: 643-58.
16. Maki K.,Watabe E., Iguchi Y., Nakamura H., Tomishima M., Ohki H. et al. (2006) Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole. Microbiol Immunol 50: 281-92.
17. Maki K., Holmes A. R.,Watabe E., Iguchi Y.,Matsumoto S., Ikeda F. et al. (2007) Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations. Microbiol Immunol 51: 1053-9.
18. Odabasi Z., Paetznick V., Rex J.H., Ostrosky-Zeichner L. (2007) Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51: 4214-16.
19. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., Perlin D.S. (2007) Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 51: 2253-6.
20. Wiederhold N.P., Najvar L.K., Bocanegra R., Molina D., Olivo M., Graybill J.R. (2007) In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 51: 1616-20.
21. Zhanel G.G., Saunders D.G., Hoban D.J., Karlowsky J.A. (2001) Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 45: 2018-22.
22. Kanasaki R., Abe F., Furukawa S., Yoshikawa K., Fujie A., Hino M. et al. (2006) FR209602 and related compounds, novel antifungal lipopeptides from Coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity. J Antibiot 59: 145-8.
23. National Committee for Clinical Laboratory Standards. (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards,Wayne, PA.
24. Sakamoto H., Hirose T., Nakamoto S., Hatano K., Shibayama F., Kikuchi H. et al. (1988) Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. J Antibiot 41: 1896-905.
25. Theuretzbacher U. (2004) Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 23: 805-12.
26. Louie A., Deziel M., LiuW., Drusano M.F., Gumbo T., Drusano G.L. (2005) Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49: 5058-68.
27. Paderu P., Park S., Perlin D.S. (2004) Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 48: 3845-9.
28. Andes D., Marchillo K., Lowther J., Bryskier A., Stamstad T., Conklin R. (2003) In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47: 1187-92.
29. Wiederhold N.P., Kontoyiannis D. P., Chi J., Prince R.A., Tam V.H., Lewis R.E. (2004) Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190: 1464-71.
30. Banerjee D., Martin N., Nandi S., Shukla S., Dominguez A., Mukhopadhyay G. et al. (2007) A genome-wide steroid response study of the major human fungal pathogen Candida albicans. Mycopathologia 164: 1-17.
31. Larsen B., Anderson S., Brockman A., Essmann M., Schmidt M. (2006) Key physiological differences in Candida albicans CDR1 induction by steroid hormones and antifungal drugs. Yeast 23: 795-802.
32. Lepak A., Nett J., Lincoln L., Marchillo K., Andes D. (2006) Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob Agents Chemother 50: 1311-19.
33. Nakayama H., Tanabe K., Bard M., HodgsonW.,Wu S., Takemori D. et al. (2007) The Candida glabrata putative sterol transporter gene CgAUS1 protects cells against azoles in the presence of serum. J Antimicrob Chemother 60: 1264-72.
34. Yang Y.L., Lin Y.H., Tsao M.Y., Chen C.G., Shih H.I., Fan J.C. et al. (2006) Serum repressing efflux pump CDR1 in Candida albicans. BMC Mol Biol 7: 22.